Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Income: 2020-2025

Historic Net Income for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.

  • Fulcrum Therapeutics' Net Income rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Net Income stood at -$19.6 million for Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Net Income registered a high of $55.4 million during Q2 2024, and its lowest value of -$34.1 million during Q2 2022.
  • Moreover, its 3-year median value for Net Income was -$22.7 million (2023), whereas its average is -$14.4 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Net Income spiked by 332.98% in 2024, and later slumped by 131.86% in 2025.
  • Fulcrum Therapeutics' Net Income (Quarterly) stood at -$23.5 million in 2021, then declined by 11.29% to -$26.1 million in 2022, then climbed by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then rose by 9.68% to -$19.6 million in 2025.
  • Its Net Income stands at -$19.6 million for Q3 2025, versus -$17.7 million for Q2 2025 and -$16.6 million for Q4 2024.